KMPH KemPharm
- 5.810
- 0.0000.00%
KemPharm News
10-Q: Q2 2024 Earnings Report
10-Q: Q1 2024 Earnings Report
StockNews.com Initiates Coverage on Zevra Therapeutics (NASDAQ:KMPH)
Zevra Therapeutics (NASDAQ:KMPH) Coverage Initiated by Analysts at StockNews.com
Zevra Therapeutics (NASDAQ:KMPH) Receives New Coverage From Analysts at StockNews.com
Zevra Therapeutics, Inc. (NASDAQ:KMPH) Short Interest Down 5.5% in February
Zevra Therapeutics (KMPH) Set to Announce Quarterly Earnings on Tuesday
Zevra Therapeutics Starts Trading Under ZVRA Ticker Symbol on Nasdaq
Zevra Therapeutics Begins Trading As ZVRA; Formerly KemPharm, Inc.
Verve Therapeutics (NASDAQ:VERV) Vs. KemPharm (NASDAQ:KMPH) Head-To-Head Review
Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results
Zevra Therapeutics Says Arimoclomol Research Featured In Two Poster Presentations At 19th Annual WORLDSymposium 2023
KemPharm Changes Name To Zevra Therapeutics, Inc.; To Trade On Nasdaq Under New Ticker Symbol "ZVRA" Starting March 1, 2023
Short Interest in KemPharm, Inc. (NASDAQ:KMPH) Expands By 5.8%
KemPharm Enhances Senior Management Team
KemPharm, Inc. (NASDAQ:KMPH) Sees Significant Growth in Short Interest
KemPharm (NASDAQ:KMPH) Shares Pass Above Fifty Day Moving Average of $4.75
Express News | KemPharm Announces Promotion of Sven Guenther to Chief Scientific Officer, Christal Mickle to Chief Pdt Development Officer >KMPH
KemPharm Appoints Matthew Plooster as Chair, Richard Pascoe as CEO
KemPharm Announces Matthew R. Plooster Named Chairman Of The Board Of Directors And Richard W. Pascoe Appointed Chief Executive Officer
Analysis
Price Target
No Data
No Data